Companies:
51,106
Total Market Cap:
153304892694132.88
Global Rank
#15858
Country Rank
#5032
Market Cap
428.47 M
Price
0.435
Change (%)
0.30%
Volume
1.81 M
Hua Medicine (Shanghai) Ltd.'s latest marketcap:
428.47 M
As of 11/13/2025, Hua Medicine (Shanghai) Ltd.'s market capitalization has reached $428.47 M. According to our data, Hua Medicine (Shanghai) Ltd. is the 15858th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 428.47 M |
| Revenue (ttm) | 52.27 M |
| Net Income (ttm) | 151.74 M |
| Shares Out | 988.01 M |
| EPS (ttm) | 0.15 |
| Forward PE | 3.88 |
| Ex-Dividend Date | n/a |
| Earnings Date | 11/28/2025 |
Market Cap Chart
Data Updated: 11/13/2025
Hua Medicine (Shanghai) Ltd.'s yearly market capitalization.
Hua Medicine (Shanghai) Ltd. has seen its market value drop from HK$8.76 B to HK$3.33 B since 2018, representing a total decrease of 61.97% and an annual compound decline rate (CAGR) of 13.13%.
| Date | Market Cap(HK$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 11/13/2025 | HK$3.33 B | $428.47 M | 117.96% | 15858 |
| 12/31/2024 | HK$1.43 B | $184.31 M | -25.71% | 19491 |
| 12/29/2023 | HK$1.93 B | $246.83 M | -46.67% | 17595 |
| 12/30/2022 | HK$3.62 B | $462.78 M | -0.33% | 12769 |
| 12/31/2021 | HK$3.63 B | $465.12 M | -34.03% | 13812 |
| 12/31/2020 | HK$5.5 B | $708.96 M | 16.61% | 9704 |
| 12/31/2019 | HK$4.72 B | $605.01 M | -46.15% | 9113 |
| 12/31/2018 | HK$8.76 B | $1.12 B | 5769 |
Company Profile
About Hua Medicine (Shanghai) Ltd.
Hua Medicine (Shanghai) Ltd. is a drug development company specializing in diabetes therapies, primarily serving the Chinese market. Founded in 2011 and headquartered in Shanghai, the company focuses on innovative treatments for metabolic diseases.
Key Products & Research
- Dorzagliatin (HMS5552): An oral drug for Type 2 Diabetes (T2D) treatment.
- Combination Therapies: Dorzagliatin paired with Metformin, Sitagliptin, or Empagliflozin for T2D and Diabetic Kidney Disease (DKD).
- Additional Applications: Dorzagliatin combined with GLP1RA for T2D and obesity, or with insulin for Type 1 Diabetes.
- Next-Generation Solutions: Includes glucokinase (GK) inhibitors for metabolic diseases and mGLUR5 negative allosteric modulators (NAM) for Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID) and drug addiction.
Frequently Asked Questions
-
What is Hua Medicine (Shanghai) Ltd.'s (HKG-2552) current market cap?As of 11/13/2025, Hua Medicine (Shanghai) Ltd. (including the parent company, if applicable) has an estimated market capitalization of $428.47 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Hua Medicine (Shanghai) Ltd. (HKG-2552) rank globally by market cap?Hua Medicine (Shanghai) Ltd. global market capitalization ranking is approximately 15858 as of 11/13/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.